Finland· FI-REL-REL48700

CABOMETYX

A cabozantinib product containing cabozantinib s-malate, registered in Finland by Ipsen Pharma. The same ATC class is registered in 12 of our 19 countries.

ATC L01EX07

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedCABOMETYXATCL01EX07REGISTER NO.FI-REL-REL48700PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Cabozantinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EX07 (cabozantinib), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 7 of them publish a price we can compare per daily dose

Cabozantinib · ATC L01EX07

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cabozantinib costs, country by country.

Normalised to the WHO defined daily dose (60 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Cabozantinib · price per daily dose (60 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$570.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Cabozantinib S-malate
Manufacturer
Ipsen Pharma
Country
Finland (FI)
ATC code
L01EX07
ATC class
Cabozantinib
Defined daily dose
60 mg, O
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

544 interactions on record for cabozantinib.

Graded by severity as the source publishes them — 360 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cabozantinib · interactions on record

544 records

  • 360 severe
  • 179 moderate
  • 5 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • GranisetronA04AA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cabozantinib in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cabozantinib products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • Germany · Hasgobusno

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fab1eb3c-b2a6-4576-8872-7da79c0f05b3
GET /v1/drugs/fab1eb3c-b2a6-4576-8872-7da79c0f05b3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "60",
  "form": "tabletti, kalvopäällysteinen",
  "route": "Suun kautta",
  "ddd_unit": "mg",
  "strength": "60 mg",
  "atc_label": "kabotsantinibi",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/16/1136/006",
  "fimea_rel_id": "REL48700",
  "authorised_at": "2016-09-09"
}

See everything about cabozantinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.